John Mendlein - Net Worth and Insider Trading
John Mendlein Net Worth
The estimated net worth of John Mendlein is at least $623,802 dollars as of 2024-12-27. John Mendlein is the Director of Fate Therapeutics Inc and owns about 282,770 shares of Fate Therapeutics Inc (FATE) stock worth over $458,087. John Mendlein is also the Director of aTyr Pharma Inc and owns about 43,956 shares of aTyr Pharma Inc (ATYR) stock worth over $165,714. Details can be seen in John Mendlein's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that John Mendlein has not made any transactions after 2023-01-13 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of John Mendlein
John Mendlein Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, John Mendlein owns 5 companies in total, including Fate Therapeutics Inc (FATE) , aTyr Pharma Inc (ATYR) , and Moderna Inc (MRNA) among others .
Click here to see the complete history of John Mendlein’s form 4 insider trades.
Insider Ownership Summary of John Mendlein
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| FATE | Fate Therapeutics Inc | 2023-01-13 | director |
| ATYR | aTyr Pharma Inc | 2018-12-21 | director & CEO and Executive Chairman |
| MRNA | Moderna Inc | 2018-12-07 | See Remarks |
 | | 2016-02-02 | director |
| | 2021-07-29 | director |
John Mendlein Latest Holdings Summary
John Mendlein currently owns a total of 2 stocks. Among these stocks, John Mendlein owns 282,770 shares of Fate Therapeutics Inc (FATE) as of January 13, 2023, with a value of $458,087 and a weighting of 73.43%. John Mendlein also owns 43,956 shares of aTyr Pharma Inc (ATYR) as of December 21, 2018, with a value of $165,714 and a weighting of 26.57%.
Latest Holdings of John Mendlein
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| FATE | Fate Therapeutics Inc | 2023-01-13 | 282,770 | 1.62 | 458,087 |
| ATYR | aTyr Pharma Inc | 2018-12-21 | 43,956 | 3.77 | 165,714 |
Holding Weightings of John Mendlein
John Mendlein Form 4 Trading Tracker
According to the SEC Form 4 filings, John Mendlein has made a total of 3 transactions in Fate Therapeutics Inc (FATE) over the past 5 years, including 1 buys and 2 sells. The most-recent trade in Fate Therapeutics Inc is the acquisition of 124,679 shares on January 13, 2023, which cost John Mendlein around $698,202.
According to the SEC Form 4 filings, John Mendlein has made a total of 0 transactions in aTyr Pharma Inc (ATYR) over the past 5 years. The most-recent trade in aTyr Pharma Inc is the acquisition of 17,500 shares on December 21, 2018, which cost John Mendlein around $102,900.
Insider Trading History of John Mendlein
- 1
John Mendlein Trading Performance
GuruFocus tracks the stock performance after each of John Mendlein's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by John Mendlein is 16.08%. GuruFocus also compares John Mendlein's trading performance to market benchmark return within the same time period. The performance of stocks bought by John Mendlein within 3 months outperforms 6 times out of 9 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how John Mendlein's insider trading performs compared to the benchmark.
Performance of John Mendlein
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 18.09 | | | | | |
| Relative Return to S&P 500(%) | 15.48 | | | | | |
John Mendlein Ownership Network
John Mendlein Owned Company Details
What does Fate Therapeutics Inc do?
Who are the key executives at Fate Therapeutics Inc?
John Mendlein is the director of Fate Therapeutics Inc. Other key executives at Fate Therapeutics Inc include director & 10 percent owner Redmile Group, Llc , Chief Financial Officer Dulac Edward J Iii , and director & President and CEO J Scott Wolchko .
Fate Therapeutics Inc (FATE) Insider Trades Summary
Over the past 18 months, John Mendlein made no insider transaction in Fate Therapeutics Inc (FATE). Other recent insider transactions involving Fate Therapeutics Inc (FATE) include a net sale of 18,777 shares made by Dulac Edward J Iii , a net purchase of 100,961 shares made by Redmile Group, Llc , and a net sale of 35,237 shares made by Cindy Tahl .
In summary, during the past 3 months, insiders sold 341,633 shares of Fate Therapeutics Inc (FATE) in total and bought 397,964 shares, with a net purchase of 56,331 shares. During the past 18 months, 426,428 shares of Fate Therapeutics Inc (FATE) were sold and 442,594 shares were bought by its insiders, resulting in a net purchase of 16,166 shares.
Fate Therapeutics Inc (FATE)'s detailed insider trading history can be found in Insider Trading Tracker table.
Fate Therapeutics Inc Insider Transactions
John Mendlein Mailing Address
Above is the net worth, insider trading, and ownership report for John Mendlein. Currently GuruFocus does not have mailing address information for John Mendlein.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
